NCT05931861 - Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

December 4, 2023

Study Completion Date

December 4, 2023

Conditions

Dry Eye

Interventions

DEVICE

T2769

T2769: sodium hyaluronate 0.15%, Trehalose 3%, Naaga 2.45% in a 12.5 mL ABAK® multi-dose bottle.

Trial Locations (6)

"Medical Center Oxycom", Burgas

"Asmp Ob - Ip Glm Eood", Smolyan

"Medical Center For Eye Health Focus", Sofia

"Specialized Ophthalmological Hospital For Active Treatment Pentagram", Sofia

"Medical Center Vereya", Stara Zagora

Ambulatory For Group Practice For Specialized Medical Care For Eye Diseases - Dr. Grupchevi, Varna